24830 - Ocimum Bio

Who We Are
Who We Are

IFC is the largest global development institution focused on the private sector in developing countries. By encouraging growth, IFC advances economic development, creates jobs and improves the lives of people.
More About Us
About IFC

Our Leadership

Development Partners
Accountability

Learn more about accountability
Annual Report

Download the Report
What We Do
What We Do

IFC advances economic development and improves the lives of people by encouraging the growth of the private sector in developing countries. We achieve this by investing in impactful projects, mobilizing other investors, and sharing expertise.
What We Do Overview
SOLUTIONS

Our products and services
OUR PRIORITIES

Climate Business

Fragile & Conflict Afflicted Situations

Gender

Mobilizing Private Capital

Sustainability
SECTORS & EXPERTISE

Agribusiness & Forestry

Creative Industries

Education

Financial Institutions

Funds

Health

Infrastructure

Manufacturing

Public-Private Partnerships

Tourism, Retail & Property

Trade & Supply Chain Finance

Venture Capital

Working Upstream
Where We Work
Where We Work

As the largest global development institution focused on the private sector, IFC operates in more than 100 countries around the globe. We apply lessons learned in one region to solve problems in another.
Overview
By Region

Africa

East Asia and Pacific

Europe

Latin America and the Caribbean

Middle East and Central Asia

South Asia
Our Impact
Our Impact

Our impact improves lives. IFC brings a clear set of advantages to the world’s most challenging markets. Including a history of innovation, a global mandate, and a determination to achieve measurable development impact.
Our Impact Overview
PRINCIPLES & MEASUREMENT

Impact Investing at IFC

Measuring and Monitoring (AIMM)

Evaluation

Sustainable Development Goals (SDGs)

Owned by 186 member countries and consistently rated AAA/Aaa. IFC aims to achieve our mission of promoting development by providing debt and equity to the private sector, through a range of benchmark and bespoke products.

For Partners

For Investors

Get in Touch

Summary of Proposed Investment

Project Number

24830

Company Name

OCIMUM BIOSOLUTIONS LTD

Date SPI Disclosed

Apr 27, 2006

Country

India

Industry

Health, Education and Life Sciences

Projected Board Date

Jun 6, 2006

Status

Completed

Sector

Other Medical

Date Revised SPI Disclosed

Sep 21, 2006

Department

Regional Industry - MAS Asia & Pac

Environmental Category

B - Limited

Previous Events

Approved : Nov 1, 2006
Signed : Nov 3, 2006
Invested : Nov 8, 2006

Project Description

Ocimum Biosolutions Ltd. (Ocimum or the company) is a small sized, fast growing firm that provides contract research outsourcing (CRO) services to pharmaceutical and biotechnology companies & research organizations globally. Ocimum, with India as its base and subsidiaries in the US and Germany, recently acquired the Genomic Diagnosis Division of MWG Biotech AG, Germany (MWG) and integrated it into its Indian operations. Ocimum offers services to universities, research centers, various labs and pharmaceutical companies including basic human disease research, genetic analysis, pharmaceutical drug discovery and development, pharmacogenomics, toxicogenomics and clinical diagnostics. It plans to invest in research and development (R&D) infrastructure and for expansion into new business lines. The company had originally requested IFC to subscribe up to $5.0 million of equity to fund its growth plans. Since the release of the original SPI on April 27, 2006, IFC’s investment has been increased to an amount of up to $6.5 million to better serve the company’s business requirements. Out of this, up to $3.9 million will be in the form of equity and up to $2.6 million will be in the form of debt.

Sponsor / Cost / Location

Product Line	IFC Investment (million USD)
Risk Management
Guarantee
Loan	2.60
Equity	3.90

Development Impact

The life sciences sector has the potential to make significant improvements in the health of the Indian population and worldwide. This is an area that is at the heart of the Millennium Development Goals, central to WBG strategy. Supporting the life science sector in the emerging markets has a number of important benefits: such as reversing the brain drain, ensuring access to high quality, cheap medicines for poor populations, providing high quality jobs, helping exports and supporting innovation, science and technology for the developing world. This biotech project will achieve a high development impact for the following reasons:

- By recruiting and training scientists to perform drug research services, this project supports global efforts in increasing developing country resources working on improving human health.

- India has already an emerging biotechnology industry. This project will help develop an internationally competitive CRO in India. Contract research outsourcing is a fast growing industry where India could become as competitive as in information technology.

- This project will also foster the development of a high-technology base in developing countries and the transfer of technology from North to South.

This is a Category B project according to IFC’s Procedure for Environmental and Social Review of Projects because limited environmental and social impacts can be mitigated by adhering to industry best practices, recognized performance standards, guidelines, and/or design criteria. Environmental, health/safety, and social issues that may be associated with this project include:

- minimization of organic solvent usage,
- minimization of animal experiments,
- wastewater treatment and discharge,
- air emissions,
- solid and hazardous waste disposal,
- hazardous material management,
- occupational health and safety programs,
- reputational issues, and
- community relationship and development.

These issues will be reviewed during project appraisal to ensure the compliance with World Bank Group/IFC policies and guidelines.
Location of environmental documents In locally affected community
6th Floor, Reliance Classic
Road No 1, Banjara Hills
Hyderabad - 500 034
A.P., India

Contacts

For Inquiries About the Project, Contact

Mr. Subash Lingareddy, Founder & CFO
6th Floor, Reliance Classic
Road No 1, Banjara Hills
Hyderabad - 500 034
A.P., India
Telephone: +91 40 5562 7200
Fax: +91 40 5562 7205

This Summary of Project Information (SPI) is prepared and distributed to the public in advance of the IFC Board of Directors' consideration of the proposed transaction. Its purpose is to enhance the transparency of IFC's activities, and this document should not be construed as presuming the outcome of the Board decision. Board dates are estimates only. The following SPI is disclosed in accordance with IFC's Disclosure of Information Policy that went into effect September 1998.

The map is for illustrative purposes and does not imply the expression of any opinion on the part of the World Bank, concerning the legal status of any country or territory or concerning the delimitation of frontiers or boundaries. Country borders or names do not necessarily reflect the World Bank Group's official position. In some cases, available project location information is limited to the country of the project's activities. Locations are approximate.

Projects

Summary of Proposed Investment

Project Description

Sponsor / Cost / Location

Project Sponsor and Major Shareholders of Project Company

Total Project Cost and Amount and Nature of IFC's Investment

Board Approved IFC Investment

Location of Project and Description of Site

Development Impact

IFC's Expected Development Contribution

Environmental and Social Issues - Category

Press-Release

Related ESRS/ERS

Similar Projects

Contacts

Disclaimer